Marquette Asset Management, LLC Adverum Biotechnologies, Inc. Transaction History

Marquette Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$1.5 - $2.33 $91,909 - $142,766	-61,273 Reduced 50.47%	60,120 $90,000
Q4 2022 Jan 12, 2023	BUY	$0.54 - $10.3 $13,220 - $252,174	24,483 Added 25.26%	121,393 $0
Q3 2022 Oct 06, 2022	SELL	$0.96 - $9.68 $34,424 - $347,115	-35,859 Reduced 27.01%	96,910 $0
Q2 2022 Jul 15, 2022	BUY	$0.81 - $1.34 $54,282 - $89,800	67,015 Added 101.92%	132,769 $159,000
Q1 2022 Apr 26, 2022	BUY	$1.23 - $1.95 $14,457 - $22,920	11,754 Added 21.77%	65,754 $86,000
Q4 2021 Jan 19, 2022	BUY	$1.74 - $2.4 $14,610 - $20,152	8,397 Added 18.41%	54,000 $95,000
Q3 2021 Oct 12, 2021	BUY	$2.08 - $3.6 $94,854 - $164,170	45,603 New	45,603 $99,000
Q4 2017 Jan 10, 2018	SELL	$2.85 - $3.95 $74,094 - $102,692	-25,998 Closed	0 $0
Q3 2017 Oct 10, 2017	BUY	$2.45 - $3.65 $63,695 - $94,892	25,998	25,998 $95,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Marquette Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Marquette Asset Management, LLC with notifications on news.